Risedronic acid

Base Information

• Chemical Name: Risedronic acid
• CAS No.: 105462-24-6
• Molecular Formula: C7H11NO7P2
• Molecular Weight: 283.114
• Hs Code.: 2933399090
• European Community (EC) Number: 600-654-2,601-362-8,658-043-1
• UNII: KM2Z91756Z
• DSSTox Substance ID: DTXSID2023563
• Nikkaji Number: J476.065D
• Wikipedia: Risedronic_acid
• Wikidata: Q408724
• NCI Thesaurus Code: C66517
• RXCUI: 55685
• Pharos Ligand ID: 1NLT2P49THM9
• Metabolomics Workbench ID: 43159
• ChEMBL ID: CHEMBL923
• Mol file: 105462-24-6.mol

Synonyms:1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate;2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate;2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate;Actonel;Atelvia;Bisphosphonate Risedronate Sodium;risedronate;risedronate sodium;Risedronate Sodium, Bisphosphonate;risedronic acid;risedronic acid, monosodium salt;Sodium, Bisphosphonate Risedronate

Chemical Property of Risedronic acid

Chemical Property:

• Appearance/Colour: white crystal powder
• Vapor Pressure: 4.03E-20mmHg at 25°C
• Refractive Index: 1.651
• Boiling Point: 692.3 °C at 760 mmHg
• PKA: 1.41±0.10(Predicted)
• Flash Point: 372.5 °C
• PSA: 167.80000
• Density: 1.87 g/cm³
• LogP: -0.37440
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility.: Aqueous Base (Slightly), Methanol (Very Slightly, Heated, Sonicated)
• XLogP3: -3.1
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 283.00107569
• Heavy Atom Count: 17
• Complexity: 339

Purity/Quality:

99% ^*data from raw suppliers

RisedronicAcid ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
• Recent ClinicalTrials: Prophylactic Riserodrenate for Patients With Peripheral Lung Tumors Treated With SBRT
• Recent EU Clinical Trials: Do bisphosphonates alter the skeletal response to mechanical stimulation in children with osteogenesis imperfecta?
• Recent NIPH Clinical Trials: 36-month Special Drug Use Surveillance on Frequency of Bone Fractures with Sodium Risedronate 75 mg Tablets
• Uses: Risedronic acid is a potentially useful biophosphonate for bone resorption analysis. Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor.

Technology Process of Risedronic acid

There total 10 articles about Risedronic acid which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 95.8%

pyridyl-3-yl-acetic acid (501-81-5) → risedronic acid (105462-24-6)

Guidance literature:

With phosphoric acid; phosphorus trichloride; In chlorobenzene; at 90 - 95 ℃; for 2.5h;

Reference yield: 82.0%

3-pyridineacetic acid hydrochloride (6419-36-9) + phosphorus trichloride (7719-12-2,52843-90-0) → risedronic acid (105462-24-6)

Guidance literature:

3-pyridineacetic acid hydrochloride; phosphorus trichloride; In water; at 0 - 80 ℃; for 1h;

With water; for 6h; Heating / reflux;

Reference yield: 80.0%

3-pyridineacetic acid hydrochloride (6419-36-9) → risedronic acid (105462-24-6)

Guidance literature:

3-pyridineacetic acid hydrochloride; With phosphonic Acid; 4-nitro-phenol; at 90 ℃; for 2h;

With phosphorus trichloride; at 90 ℃; for 6h;

With water; at 19 ℃; for 12h; Reflux;

DOI:10.1021/acs.molpharmaceut.5b00670

upstream raw materials:

pyridyl-3-yl-acetic acid

3-pyridineacetic acid hydrochloride

phosphorus trichloride

phosphorous acid

Downstream raw materials:

C₁₇H₂₃N₂O₁₀P₂⁽¹⁺⁾

C₁₇H₂₃N₂O₉P₂⁽¹⁺⁾

[[1-hydroxy-2-(3-pyridinyl)-]ethylidene]bisphosphonic acid monomethyl ester

Refernces

• 1、 Massey, Ashley S.,Pentlavalli, Sreekanth,Cunningham, Richard,McCrudden, Cian M.,McErlean, Emma M.,Redpath, Philip,Ali, Ahlam A.,Annett, Stephanie,McBride, John W.,McCaffrey, Joanne,Robson, Tracy,Migaud, Marie E.,McCarthy, Helen O.. "Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA". . p. 1217 - 1228. Retrieved 2016.
• 2、 Mustafa, Dana A.,Kashemirov, Boris A.,McKenna, Charles E.. "Microwave-assisted synthesis of nitrogen-containing 1- hydroxymethylenebisphosphonate drugs". . p. 2285 - 2287. Retrieved 2011.
• 3、 Grün, Alajos,Kovács, Rita,Garadnay, Sándor,Greiner, István,Keglevich, Gy?rgy. "The synthesis of risedronic acid and alendronate applying phosphorus oxychloride and phosphorous acid in methanesulfonic acid". . p. 253 - 258. Retrieved 2015.
• 4、 Grün, Alajos,Rádai, Zita,S?regi-Nagy, Dávid Illés,Greiner, István,Keglevich, Gy?rgy. "Rational synthesis of α-hydroxyphosphonic derivatives including dronic acids". . p. 386 - 387. Retrieved 2019/01/18.
• 5、 Yanvarev,Korovina,Usanov,Khomich,Veps?l?inen,Puljula,Kukhanova,Kochetkov. "Methylene bisphosphonates as the inhibitors of HIV RT phosphorolytic activity". . p. 153 - 162. Retrieved 2016/06/13.